https://www.pharmaradar360.com/article/0294d9e731c9c3fdPharmaRadar360en2026-04-18T16:29:00.000ZPotent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humanshttps://www.pharmaradar360.com/article/da6d995376702ffcPharmaRadar360en2026-04-18T14:08:55.000ZIt doesn’t matter how much you sit — walking more could lower your risk of death and diseasehttps://www.pharmaradar360.com/article/0a4c993a8c315e0cPharmaRadar360en2026-04-18T13:48:37.000ZUFRJ reúne professores eméritos em articulação permanente por ideias e soluções para a universidadehttps://www.pharmaradar360.com/article/6ba122f96e0e47d7PharmaRadar360en2026-04-18T13:05:40.000ZLive Updates From the AACR Annual Meeting 2026: Saturday, April 18https://www.pharmaradar360.com/article/c65a776f458dcef8PharmaRadar360en2026-04-18T10:00:24.000ZRevMed’s stunning success; FDA to reclassify peptides; and morehttps://www.pharmaradar360.com/article/689dc2fdedbc1cfaPharmaRadar360en2026-04-18T08:34:06.000ZOur Research Group at the PBP World Meeting 2026https://www.pharmaradar360.com/article/f0faa58cb542074cPharmaRadar360en2026-04-18T07:32:36.000ZArtificial neurons successfully communicate with living brain cellshttps://www.pharmaradar360.com/article/c7744c44b1319105PharmaRadar360en2026-04-18T07:30:00.000ZSevere malaria may affect children’s cognitive abilities more than a decade laterhttps://www.pharmaradar360.com/article/174a7343aba79ffcPharmaRadar360en2026-04-18T06:29:00.000ZZelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trialhttps://www.pharmaradar360.com/article/88f4be1eb796b231PharmaRadar360en2026-04-18T06:29:00.000ZZelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSVhttps://www.pharmaradar360.com/article/cc52e31ee9330290PharmaRadar360en2026-04-18T03:27:27.000ZEating more fruits and vegetables tied to unexpected lung cancer riskhttps://www.pharmaradar360.com/article/0aef460b1901a96aPharmaRadar360en2026-04-18T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/d948d382ef12f4e6PharmaRadar360en2026-04-18T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/c7928f0b322465ffPharmaRadar360en2026-04-18T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/28b243d3630c33efPharmaRadar360en2026-04-18T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/be9e23a8870b11a6PharmaRadar360en2026-04-18T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/100fb70977f3d18dPharmaRadar360en2026-04-18T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/e32654f0a8cc2a1dPharmaRadar360en2026-04-18T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/e127815f1f89cc02PharmaRadar360en2026-04-18T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/b8485bbeb48ffcefPharmaRadar360en2026-04-18T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/989a32fec3f6c0cbPharmaRadar360en2026-04-18T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/87556421a375faa5PharmaRadar360en2026-04-18T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/3f6a35c16f5ddbf4PharmaRadar360en2026-04-18T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/e6a4e6a82a5fc9f7PharmaRadar360en2026-04-18T00:00:00.000Z6203https://www.pharmaradar360.com/article/6c719d61c43b8772PharmaRadar360en2026-04-18T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/3b381c66da1260fePharmaRadar360en2026-04-17T23:33:00.000ZAACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’https://www.pharmaradar360.com/article/5a13a2c4d22764d3PharmaRadar360en2026-04-17T21:04:45.000ZPew Biomedical Scholars – Limited Submissionhttps://www.pharmaradar360.com/article/6c27b0b8e0af5c65PharmaRadar360en2026-04-17T21:03:48.000ZInnovación UC reemplaza la evaluación subjetiva del vino por datos medibleshttps://www.pharmaradar360.com/article/e6b126e68bc66b7ePharmaRadar360en2026-04-17T20:53:13.000ZIn hopeful sign for biotech, obesity treatment firm Kailera raises $625 million in upsized IPOhttps://www.pharmaradar360.com/article/eca3ec74a72c0f80PharmaRadar360en2026-04-17T20:51:24.000ZKailera nets $625M in one of biotech’s biggest-ever IPOshttps://www.pharmaradar360.com/article/e138125857acf074PharmaRadar360en2026-04-17T20:30:00.000ZUNFPA Funding and Kemp-Kasten: An Explainerhttps://www.pharmaradar360.com/article/ec777a0bc4db0133PharmaRadar360en2026-04-17T20:21:42.000ZTunneling Neurons in Adult Bird Brains Provide New Insights into Neurogenesishttps://www.pharmaradar360.com/article/df017f2bf95d1579PharmaRadar360en2026-04-17T20:00:00.000ZNotice of REDCap data security incidenthttps://www.pharmaradar360.com/article/9b393ddab24317faPharmaRadar360en2026-04-17T19:59:39.000ZExplore Carolina’s botanical history at the garden tourhttps://www.pharmaradar360.com/article/ab6f0ab116f7b43ePharmaRadar360en2026-04-17T19:54:40.000ZKelly Rhys-Jones - Chief People Officerhttps://www.pharmaradar360.com/article/1ed2296e0eed482ePharmaRadar360en2026-04-17T19:47:55.000ZTargeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Modelshttps://www.pharmaradar360.com/article/59c0505b24b6c149PharmaRadar360en2026-04-17T19:36:15.000ZInside the insect collection at the University of Minnesotahttps://www.pharmaradar360.com/article/4dba60fb2aac761fPharmaRadar360en2026-04-17T19:35:42.000ZU of M researchers launch startup aiming to reduce AI energy consumptionhttps://www.pharmaradar360.com/article/46c01b0b9f9fb3b8PharmaRadar360en2026-04-17T19:34:48.000ZUniversity of Minnesota med school dean shares ‘innovation and vision’ on visit to St. Cloudhttps://www.pharmaradar360.com/article/e0770cd677e5db19PharmaRadar360en2026-04-17T19:31:35.000ZNext-generation clinical research: An integrated solution for pre-screeninghttps://www.pharmaradar360.com/article/f6236872dba2a5afPharmaRadar360en2026-04-17T19:29:00.000ZDiscovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseaseshttps://www.pharmaradar360.com/article/e67bad4f30796727PharmaRadar360en2026-04-17T19:22:12.000ZInSet® Interview with Dr. Veronica Diazhttps://www.pharmaradar360.com/article/95cad6bd54eb918cPharmaRadar360en2026-04-17T19:01:38.000ZZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platformhttps://www.pharmaradar360.com/article/43283caaf0ec7f72PharmaRadar360en2026-04-17T18:29:55.000Z'Defer to breast cancer diagnosis and treatment experts': Imaging leaders rail against new ACP breast cancer screening recshttps://www.pharmaradar360.com/article/525c92782b5e4919PharmaRadar360en2026-04-17T18:29:00.000ZTwo Northeast Ohio changemakers triumph in competition to end cardiovascular diseasehttps://www.pharmaradar360.com/article/61c7b37be3a7c75fPharmaRadar360en2026-04-17T18:15:00.000ZProfessor Michael Laub and MIT alumni named 2025 AAAS Fellowshttps://www.pharmaradar360.com/article/bcb3511927a71027PharmaRadar360en2026-04-17T18:04:00.000ZQ&A: Understanding Pneumococcal Disease Burden and Vaccine Opportunitieshttps://www.pharmaradar360.com/article/993cf944321af3b1PharmaRadar360en2026-04-17T17:58:00.000ZLocal construction executive advances awareness, advocacy and heart health education in Browardhttps://www.pharmaradar360.com/article/cf8272767007f3a6PharmaRadar360en2026-04-17T17:47:48.000ZNew mammogram policy: Maryland to require BAC notifications with first law of its kindhttps://www.pharmaradar360.com/article/0470c9bfe2587856PharmaRadar360en2026-04-17T17:35:00.000ZUBC researchers aim to deliver earlier warnings on the toxic drug supplyhttps://www.pharmaradar360.com/article/aada987eba981d03PharmaRadar360en2026-04-17T17:31:00.000ZFounder and CEO raises awareness and funds to end women’s No. 1 health threathttps://www.pharmaradar360.com/article/621a8e54844efad0PharmaRadar360en2026-04-17T17:17:43.000ZNew CDC pick Schwartz is praised by public health proshttps://www.pharmaradar360.com/article/d5a21fa735264fcePharmaRadar360en2026-04-17T17:16:11.000ZFor What’s Next: Preparing Today’s Lab or Tomorrow’s Discoverieshttps://www.pharmaradar360.com/article/ea70114e186245dfPharmaRadar360en2026-04-17T17:07:11.000ZSK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targetshttps://www.pharmaradar360.com/article/32cf592412ebdfd6PharmaRadar360en2026-04-17T16:59:12.000ZFDA Approves Sotyktu From Bristol Myers Squibbhttps://www.pharmaradar360.com/article/83e929de77cf4b88PharmaRadar360en2026-04-17T16:58:12.000ZWhat Are the Recent Trends in Employer-Based Health Coverage?https://www.pharmaradar360.com/article/5e610ce54e3cf7c7PharmaRadar360en2026-04-17T16:49:25.000ZSPECIAL FEATURE - Bioavailability & Solubility: Experimental Techniques Combined With Computational Decision-Making Rapidly ID the Most Viable Enhancement Pathwayhttps://www.pharmaradar360.com/article/0f337f84ff934283PharmaRadar360en2026-04-17T16:47:51.000ZWhich Pregnancy Symptoms Require Urgent Care?https://www.pharmaradar360.com/article/e7450411df0a56dfPharmaRadar360en2026-04-17T16:40:11.000ZThe State of Multiomics & NGShttps://www.pharmaradar360.com/article/777fae8f4db6ecbcPharmaRadar360en2026-04-17T16:33:00.000ZNine Intermountain Health Hospitals Named to Nation’s 2026 100 Top Hospitals by Modern Healthcare and Premierhttps://www.pharmaradar360.com/article/c0351d9cdc64344bPharmaRadar360en2026-04-17T16:31:27.000Zcontextflow collaborates with VUNO and Mesalvo to advance cardiac arrest prediction solutionhttps://www.pharmaradar360.com/article/dbadf1c70368cb8ePharmaRadar360en2026-04-17T16:30:00.000ZDe-escalating Treatment in HER2-Positive Breast Cancer: Doing More With Lesshttps://www.pharmaradar360.com/article/65c209eca4ddc2d5PharmaRadar360en2026-04-17T16:29:00.000ZEPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Modelhttps://www.pharmaradar360.com/article/9a35214c11b1325dPharmaRadar360en2026-04-17T16:20:00.000ZProposed DTW Cigar Lounge Puts Smoke‑Free Protections at Riskhttps://www.pharmaradar360.com/article/3be8f271c3e76be4PharmaRadar360en2026-04-17T16:06:25.000ZKailera IPO interview: CEO Renaud talks biotech market, China and obesity pipelinehttps://www.pharmaradar360.com/article/662ec5b393f8d2caPharmaRadar360en2026-04-17T16:00:00.000ZInside Pharma's Revenue Engine: The Gross-to-Net Reckoninghttps://www.pharmaradar360.com/article/cde4b7cf14e2d773PharmaRadar360en2026-04-17T16:00:00.000ZOptimizing Specialty Medication Access in Community Pharmacy: A Practical Workflow Approachhttps://www.pharmaradar360.com/article/accd7bc7c48ca675PharmaRadar360en2026-04-17T16:00:00.000ZNew nominee may need a charm at the CDChttps://www.pharmaradar360.com/article/c6b9f1494c47bde7PharmaRadar360en2026-04-17T15:45:00.000ZAffordability, transparency: A look at large employers' top healthcare concernshttps://www.pharmaradar360.com/article/9ac3e9fdc81a9ccdPharmaRadar360en2026-04-17T15:38:49.000Z#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standoutshttps://www.pharmaradar360.com/article/0eca8fc837639a55PharmaRadar360en2026-04-17T15:32:00.000Z$1 Million gift will further research about congenital heart defectshttps://www.pharmaradar360.com/article/835860fceeead74cPharmaRadar360en2026-04-17T15:30:00.000ZFrom Burnout to Balance: How Walgreens' Hybrid Model Is Addressing the Pharmacyhttps://www.pharmaradar360.com/article/30190b5d487d03d5PharmaRadar360en2026-04-17T15:17:56.000ZOncology Pulse Points: ASCO WBC Growth Factors Guidelines Updatehttps://www.pharmaradar360.com/article/1b4b544da41a29e9PharmaRadar360en2026-04-17T15:16:47.000ZEli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Markethttps://www.pharmaradar360.com/article/e409826a1d76fd07PharmaRadar360en2026-04-17T15:10:29.000ZTrevi raises $150M; Spain and Boston set up biotech fundhttps://www.pharmaradar360.com/article/c4b9a5c00e283df2PharmaRadar360en2026-04-17T15:03:07.000ZIEC 62304 software safety classes: what they are and how to apply themhttps://www.pharmaradar360.com/article/9f9a730f183dd574PharmaRadar360en2026-04-17T14:35:40.000ZEmergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibilityhttps://www.pharmaradar360.com/article/db51fb73338150e1PharmaRadar360en2026-04-17T14:30:13.000ZKailera makes history with record-breaking $625m IPOhttps://www.pharmaradar360.com/article/4fbb5f2158882d77PharmaRadar360en2026-04-17T14:15:59.000ZPresident Trump Nominates Dr. Erica Schwarts for CDC Leadership Rolehttps://www.pharmaradar360.com/article/61608da20ac74394PharmaRadar360en2026-04-17T14:11:25.000ZRoche to launch global study of Elevidys following EU rejectionhttps://www.pharmaradar360.com/article/77caeb8eb2552c6cPharmaRadar360en2026-04-17T14:00:00.000ZSIDP Is Shaping the Next Era of Infectious Diseases Treatmenthttps://www.pharmaradar360.com/article/37786e8c4e3f1423PharmaRadar360en2026-04-17T14:00:00.000ZTwo scientists to receive 2026 Ralph L. Sacco Scholarships for Brain Healthhttps://www.pharmaradar360.com/article/eb6cc6558bbcd8afPharmaRadar360en2026-04-17T14:00:00.000ZNeural population dynamics and temporal context cells in macaque medial parietal cortex support temporal order memoryhttps://www.pharmaradar360.com/article/79b70cfa5ea161ebPharmaRadar360en2026-04-17T14:00:00.000ZSomatosensory input drives membrane potential dynamics in motor cortex during voluntary limb movementhttps://www.pharmaradar360.com/article/58162789abb3796bPharmaRadar360en2026-04-17T14:00:00.000ZNew transcription signals in SARS-CoV-2 reshape virus–host interactionshttps://www.pharmaradar360.com/article/eed6993fea38a121PharmaRadar360en2026-04-17T14:00:00.000ZCircadian clock gates diurnal glucose utilizationhttps://www.pharmaradar360.com/article/952409948c107903PharmaRadar360en2026-04-17T13:56:08.000ZBy leaps and bounds, she overcomes obstacleshttps://www.pharmaradar360.com/article/03ba234eaa782eabPharmaRadar360en2026-04-17T13:36:00.000ZUCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicinehttps://www.pharmaradar360.com/article/b51aa89312efebf7PharmaRadar360en2026-04-17T13:32:30.000ZBiovac gets $108M backing for vaccine factory in South Africahttps://www.pharmaradar360.com/article/960fff0cb72c68b7PharmaRadar360en2026-04-17T13:22:15.000ZTRACERx MRD Results Showcase ppmSeq’s Ultra-Sensitive ctDNA Detection at AACRhttps://www.pharmaradar360.com/article/000e15827f490f91PharmaRadar360en2026-04-17T13:20:06.000ZRevolution Medicines' buyout price soars after pancreatic cancer winhttps://www.pharmaradar360.com/article/b41669aba6ed5557PharmaRadar360en2026-04-17T13:20:00.000ZSocialRx teams up with FQHC in NYC to prescribe arts and culture for chronically ill patientshttps://www.pharmaradar360.com/article/1351e5c7900a1789PharmaRadar360en2026-04-17T13:02:00.000ZINAKhttps://www.pharmaradar360.com/article/725a18c00ec759ccPharmaRadar360en2026-04-17T12:59:56.000ZViz.ai Wins Gold Edison Award™ for Advancing AI-Driven Clinical Workflows to Improve Hemorrhage Carehttps://www.pharmaradar360.com/article/3821fa9c4c9bc33bPharmaRadar360en2026-04-17T12:58:04.000ZSpringwise case study: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturinghttps://www.pharmaradar360.com/article/2bd035e347d64bfbPharmaRadar360en2026-04-17T12:34:32.000ZDoctoral student uses machine learning to transform gene therapyhttps://www.pharmaradar360.com/article/4bb3775f66bc0468PharmaRadar360en2026-04-17T12:30:22.000ZCheshire neighbourhood care model reduces A&E attendanceshttps://www.pharmaradar360.com/article/63feb38f3b973ec9PharmaRadar360en2026-04-17T12:23:00.000ZAACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 planshttps://www.pharmaradar360.com/article/daf0446f29e306a4PharmaRadar360en2026-04-17T12:17:59.000ZFIRE sheds new light on the pension debatehttps://www.pharmaradar360.com/article/990bfb88b5256d38PharmaRadar360en2026-04-17T12:15:00.000ZImpact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancerhttps://www.pharmaradar360.com/article/83240a64e985b295PharmaRadar360en2026-04-17T12:00:53.000ZCPC Biotech Launched to Offer a Fluid Management Component Portfoliohttps://www.pharmaradar360.com/article/c10768dad1db8b75PharmaRadar360en2026-04-17T12:00:00.000ZNavigating the Clinical and Economic Burden of Endometrial Cancerhttps://www.pharmaradar360.com/article/07d49e94e83cd5e5PharmaRadar360en2026-04-17T12:00:00.000ZInspiration and Action: Final Thoughts on the Future of RSV Preventionhttps://www.pharmaradar360.com/article/db62ddab8e003ac1PharmaRadar360en2026-04-17T11:49:00.000ZEuropean Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Seasonhttps://www.pharmaradar360.com/article/e6335aa7c9011a52PharmaRadar360en2026-04-17T11:48:34.000ZReplimune cries foul on regulatory flexibility. But many Americans want a stricter FDAhttps://www.pharmaradar360.com/article/6e32d43bd04950b4PharmaRadar360en2026-04-17T11:44:33.000ZLes volets découverts sur une façade à l'Hôtel-Dieu Saint-Jacques ont révélé leurs premiers secrets !https://www.pharmaradar360.com/article/3a4f6010791f3f81PharmaRadar360en2026-04-17T11:44:05.000ZScientists discover bacteria can “explode” to spread antibiotic resistancehttps://www.pharmaradar360.com/article/1762d64187f73ddaPharmaRadar360en2026-04-17T11:38:00.000ZOver 80% of PCPs concerned about financial stability over next several yearshttps://www.pharmaradar360.com/article/7f66cf3be2405f22PharmaRadar360en2026-04-17T11:28:56.000ZKailera raises $625M IPO in biotech recordhttps://www.pharmaradar360.com/article/27c54dd884c0ca22PharmaRadar360en2026-04-17T11:22:47.000ZJudge dismisses CVS-Aetna’s lawsuit against Radiology Partnershttps://www.pharmaradar360.com/article/cb046e2224b00eb8PharmaRadar360en2026-04-17T11:22:40.000ZΑνάκληση παρτίδων των καθετήρων μπαλονιού κρυοκατάλυσης POLARx και POLARx FIT, των κατευθυνόμενων θηκαρίων POLARSHEATHhttps://www.pharmaradar360.com/article/cdef01ceb2c9e2e3PharmaRadar360en2026-04-17T11:15:32.000ZLilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggestshttps://www.pharmaradar360.com/article/43b99ebab5020f29PharmaRadar360en2026-04-17T11:07:08.000ZRadiologist pipeline barely keeping pace with population growthhttps://www.pharmaradar360.com/article/86bc6e9365746219PharmaRadar360en2026-04-17T11:02:00.000ZIndustry Voices—DOJ jumps into 340B cases over state law, raising questions about federal plans for the programhttps://www.pharmaradar360.com/article/e323d6467268573fPharmaRadar360en2026-04-17T11:00:50.000ZNovartis' Vas Narasimhan heads to Anthropic's board; Metsera alum joins Structure as COOhttps://www.pharmaradar360.com/article/926d377a6970266ePharmaRadar360en2026-04-17T11:00:01.000ZHelsinki Animal Law Conference 2026: “Reimagining Justice Across Species”https://www.pharmaradar360.com/article/1f3d10895fda5107PharmaRadar360en2026-04-17T10:56:37.000ZRadiologists earning an average of $571,000, up 9% year over yearhttps://www.pharmaradar360.com/article/cf8a2729689dbd44PharmaRadar360en2026-04-17T10:50:00.000ZFDA's accelerated approval pathway needs stronger transparency, evidence standards: ICERhttps://www.pharmaradar360.com/article/9960d3d9c1ec7dcfPharmaRadar360en2026-04-17T10:47:11.000ZNew data raise concern about Medicare quality payment program, radiology experts sayhttps://www.pharmaradar360.com/article/d047365a7d998e18PharmaRadar360en2026-04-17T10:37:12.000ZEarth Day: Putting Science at the Heart of Planetary Balancehttps://www.pharmaradar360.com/article/92f19933cda36acaPharmaRadar360en2026-04-17T10:36:43.000ZDissertation Award for Heidelberg Historianhttps://www.pharmaradar360.com/article/c28278dbb04803d9PharmaRadar360en2026-04-17T10:20:14.000ZBrownlee Brain Health Awareness April 2026https://www.pharmaradar360.com/article/ea046412663b2fb7PharmaRadar360en2026-04-17T10:03:47.000ZLes résidents des USLD de l'Hôpital Garonne font leur cinéma !https://www.pharmaradar360.com/article/b5fcd890dd0f1c50PharmaRadar360en2026-04-17T10:02:44.000ZAcerand reports first-in-human trial results for ACE-106 therapyhttps://www.pharmaradar360.com/article/1e5484d14ccafe4bPharmaRadar360en2026-04-17T10:00:00.000ZThe Turning Point for Oral Biologics: Q&A With Morten Graugaardhttps://www.pharmaradar360.com/article/72f4cb161d38e58bPharmaRadar360en2026-04-17T10:00:00.000ZPositioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhDhttps://www.pharmaradar360.com/article/c03cf87c850ac699PharmaRadar360en2026-04-17T10:00:00.000ZBringing New Delivery Methods to Treatments: Q&A with Richard Lowenthalhttps://www.pharmaradar360.com/article/4e2f2e33662e335ePharmaRadar360en2026-04-17T09:59:24.000ZPalantir’s NHS contract could end if others ‘can do the job better’https://www.pharmaradar360.com/article/96a87828ff2fcc55PharmaRadar360en2026-04-17T09:54:34.000ZAligos and Xiamen Amoytop sign deal for HBV therapyhttps://www.pharmaradar360.com/article/d8c4b40e3578f832PharmaRadar360en2026-04-17T09:54:25.000ZΚύρια σημεία συνεδρίασης της Επιτροπής Αξιολόγησης Κινδύνου Φαρμακοεπαγρύπνησης (PRAC), 7 – 10 Απριλίου 2026https://www.pharmaradar360.com/article/873fe5679cba8bedPharmaRadar360en2026-04-17T09:53:00.000ZTeva scores in appeal as court revives $177M verdict against Lilly in migraine patent spathttps://www.pharmaradar360.com/article/ff0a746f06e0fdc6PharmaRadar360en2026-04-17T09:52:00.000ZGen AI chatbots continually struggle with differential diagnoses, Mass General Brigham study findshttps://www.pharmaradar360.com/article/d27328ff8fa956b0PharmaRadar360en2026-04-17T09:44:22.000ZThe innovators working to make in vivo cell therapy a realityhttps://www.pharmaradar360.com/article/2ea3d7c23f35fffaPharmaRadar360en2026-04-17T09:41:00.000ZOpenAI launches biotech-specific AI model dubbed GPT-Rosalindhttps://www.pharmaradar360.com/article/0efdfb6c6bb6233dPharmaRadar360en2026-04-17T09:40:09.000ZPoint of care at the point of need: Enabling malaria researchhttps://www.pharmaradar360.com/article/d0a4905b50c88e7fPharmaRadar360en2026-04-17T09:26:56.000ZBiomarker-led trials to guide the future of precision psychiatryhttps://www.pharmaradar360.com/article/6c3ea620dd5177bePharmaRadar360en2026-04-17T09:15:00.000ZNew Report Highlights Fructose as a Key Driver of Metabolic Diseasehttps://www.pharmaradar360.com/article/51ec70032fe0212aPharmaRadar360en2026-04-17T09:14:50.000ZFreedom of expression and recent incidentshttps://www.pharmaradar360.com/article/c76c95ce1d24ed71PharmaRadar360en2026-04-17T09:14:16.000ZLive Updates From the AACR Annual Meeting 2026: Friday, April 17https://www.pharmaradar360.com/article/a19ff0bb7ec5a11cPharmaRadar360en2026-04-17T09:11:51.000ZAspen Australia participates in the 2026 APP Conferencehttps://www.pharmaradar360.com/article/a7fedf996033ee86PharmaRadar360en2026-04-17T09:04:37.000ZFirst patient receives JANX014 dose in Janux’s trial for mCRPChttps://www.pharmaradar360.com/article/95420ae1d37ae686PharmaRadar360en2026-04-17T09:01:01.000ZDaiichi Sankyo and Interna partner for MNM-targeted delivery solutionshttps://www.pharmaradar360.com/article/bde58466b2c90159PharmaRadar360en2026-04-17T08:49:42.000ZNew publication describes the vesicular disease outbreaks of Seneca Valley virus in England in 2022https://www.pharmaradar360.com/article/7ed083209b475752PharmaRadar360en2026-04-17T08:48:00.000ZFierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC salehttps://www.pharmaradar360.com/article/43c302818b4a3334PharmaRadar360en2026-04-17T08:33:22.000ZConnecting communities to share the joy of doing sciencehttps://www.pharmaradar360.com/article/c1c11cc576488aadPharmaRadar360en2026-04-17T08:30:36.000ZTervetuloa avoimen julkaisemisen webinaareihin toukokuussahttps://www.pharmaradar360.com/article/56186a49a27f4990PharmaRadar360en2026-04-17T08:11:45.000ZRADIA Seminar: Gender, Misogyny and Extremismhttps://www.pharmaradar360.com/article/0077b4585d6a9e20PharmaRadar360en2026-04-17T08:07:42.000ZNUM4Rare: Präsenz-Kick-Off bringt Projektpartner*innen zusammenhttps://www.pharmaradar360.com/article/0fee04d20b0f95c7PharmaRadar360en2026-04-17T08:04:00.000ZIm Portrait: PD Dr. Sarah Sonnenscheinhttps://www.pharmaradar360.com/article/ac00728d30e25a86PharmaRadar360en2026-04-17T08:00:00.000ZIDIBAPS presents the Strategic Plan 2025-2028https://www.pharmaradar360.com/article/19df308bb4844852PharmaRadar360en2026-04-17T08:00:00.000ZGrundlegend neuer Therapieansatz gegen Mukoviszidose: Nanobody repariert Zelldefekthttps://www.pharmaradar360.com/article/a186b0493579fc83PharmaRadar360en2026-04-17T08:00:00.000ZA fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defecthttps://www.pharmaradar360.com/article/88617c4d0ba336caPharmaRadar360en2026-04-17T07:52:53.000ZMore information leads to more accurate beliefs—except in echo chambershttps://www.pharmaradar360.com/article/83d3c5118f9af212PharmaRadar360en2026-04-17T07:44:47.000ZDispositifs médicaux et dispositifs médicaux de diagnostic in vitro : un arbre décisionnel pour aider les acteurs concernés par l’article 10bis des règlements européenshttps://www.pharmaradar360.com/article/2294f21f07d72e1cPharmaRadar360en2026-04-17T07:41:34.000Zเตรียมตัวพบกับ! งานบ้านและสวนแฟร์ ขอนแก่น บ้านเฮามักม่วน 2026https://www.pharmaradar360.com/article/f8d21881d66905cbPharmaRadar360en2026-04-17T07:41:20.000ZCardiac MR for Every Radiologist: ESR steps up training effortshttps://www.pharmaradar360.com/article/029f87ab631483b3PharmaRadar360en2026-04-17T07:30:00.000ZRate shock looming, but uncertainty dominates: Huisman warns of a ‘serious problem’https://www.pharmaradar360.com/article/206551bd14516dc7PharmaRadar360en2026-04-17T07:28:17.000Zอมรินทร์เปิดเวทีค้นหา “นักพัฒนาชุมชนพอเพียงรุ่นใหม่”https://www.pharmaradar360.com/article/823ce2006bfd78eePharmaRadar360en2026-04-17T07:20:10.000ZΑνάκληση του συμπληρώματος διατροφής MemoVigor2, δισκία, με αρ. παρτίδας Ι015 και ημερομηνία λήξης 02/2027https://www.pharmaradar360.com/article/15fa2b246731e819PharmaRadar360en2026-04-17T07:17:58.000ZCan sparkling water boost metabolism and help with weight loss?https://www.pharmaradar360.com/article/5372eff56879110ePharmaRadar360en2026-04-17T07:02:00.000ZAbbott lowers EPS guidance on Exact Sciences buy as shares slidehttps://www.pharmaradar360.com/article/86522f3ea8a421f0PharmaRadar360en2026-04-17T07:00:00.000ZTake on Dr. Davies in the Chancellor’s Push-Up Challengehttps://www.pharmaradar360.com/article/8e37b81c6fa7978fPharmaRadar360en2026-04-17T06:58:00.000ZDr. Bennett named dentistry’s executive associate deanhttps://www.pharmaradar360.com/article/44fa1f595f7a7cffPharmaRadar360en2026-04-17T06:56:00.000ZChild Health Research Institute releases inaugural annual reporthttps://www.pharmaradar360.com/article/e91a4afefad4a3cfPharmaRadar360en2026-04-17T06:54:00.000ZUNMC for the record, April 17, 2026https://www.pharmaradar360.com/article/811f1f564281e7aaPharmaRadar360en2026-04-17T06:47:24.000ZFünf Jahre COVID-19-Impfungen – was wissen wir heute?https://www.pharmaradar360.com/article/736b1a48271075b5PharmaRadar360en2026-04-17T06:43:25.000ZFira in våren med en japansk picknick i Botaniskahttps://www.pharmaradar360.com/article/b40cfcf61ec2a54aPharmaRadar360en2026-04-17T06:30:21.000ZDigital Health’s monthly roundup of contracts and go liveshttps://www.pharmaradar360.com/article/811d80a41a6e6551PharmaRadar360en2026-04-17T06:20:00.000Z#MalattieRare. Emofilia: dalla ricerca alle nuove generazioni di specialisti, il futuro della curahttps://www.pharmaradar360.com/article/03c0bdbb5ca63678PharmaRadar360en2026-04-17T06:18:00.000ZBIO comes out swinging with 'Fight of Our Lives' campaign for the industry’s 50th birthdayhttps://www.pharmaradar360.com/article/a6a1b0a875b85061PharmaRadar360en2026-04-17T06:00:00.000ZOtsuka Pharmaceutical Receives Judges' Special Award at MAFF's 10th Shokuiku Activity Awards "MoguMogu Town" App Recognized for Promoting Food and Nutrition Educationhttps://www.pharmaradar360.com/article/f478e127462d8309PharmaRadar360en2026-04-17T05:58:55.000Zゴールデンウィーク期間中の院内施設休業日についてhttps://www.pharmaradar360.com/article/e05d39db1e894765PharmaRadar360en2026-04-17T05:58:06.000ZRedevelopment announced for Dandenong Hospitalhttps://www.pharmaradar360.com/article/f22f952f7a3c4b23PharmaRadar360en2026-04-17T04:44:00.000ZKailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPOhttps://www.pharmaradar360.com/article/959c7fc37bc9dc4aPharmaRadar360en2026-04-17T04:00:37.000ZWuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Yearhttps://www.pharmaradar360.com/article/f538cd70a12226b8PharmaRadar360en2026-04-17T03:49:55.000ZScientists discover natural hormone that reverses obesityhttps://www.pharmaradar360.com/article/183321ac3f169b81PharmaRadar360en2026-04-17T03:28:07.000ZScientists supercharge immune cells to destroy cancer more effectivelyhttps://www.pharmaradar360.com/article/c2e536b5d839b2c5PharmaRadar360en2026-04-17T03:20:00.000ZAfter long wait, Trump nominates a CDC directorhttps://www.pharmaradar360.com/article/de7d491cb6aa68c0PharmaRadar360en2026-04-17T02:58:28.000ZA “death” protein may be the key to slowing aging at its sourcehttps://www.pharmaradar360.com/article/0a658feab697e8d8PharmaRadar360en2026-04-17T02:18:03.000ZEnough Will They-Won’t They! FDA Pushes for Permanent Rare Pediatric Disease PRVshttps://www.pharmaradar360.com/article/d7da353ccb69d4d3PharmaRadar360en2026-04-17T01:55:00.000ZMagnetic robots could help remove dangerous nanoplastics from waterhttps://www.pharmaradar360.com/article/0a480744a7fc1265PharmaRadar360en2026-04-17T01:22:33.000ZStem Cell Editing Programs the Immune System to Make Own Therapeutic Proteinshttps://www.pharmaradar360.com/article/31977c4fe279255aPharmaRadar360en2026-04-17T01:05:00.000ZArtificially engineered sea ice grows—but can’t withstand the thawhttps://www.pharmaradar360.com/article/a575e8ea4849f5e4PharmaRadar360en2026-04-17T00:00:00.000ZSanten China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Products in the Chinese Mainlandhttps://www.pharmaradar360.com/article/4325064363b5a570PharmaRadar360en2026-04-17T00:00:00.000ZSupervoxel-based multimodal MRI biomarkers reveal tumor heterogeneity in high-grade glioma for prognostic stratification and therapy response predictionhttps://www.pharmaradar360.com/article/e80e12947137c0e2PharmaRadar360en2026-04-17T00:00:00.000ZContext defines precision: rethinking KRAS inhibition in oncologyhttps://www.pharmaradar360.com/article/a80f081e87eb9369PharmaRadar360en2026-04-17T00:00:00.000ZPredicting primary resistance to third-generation EGFR-TKIs in lung adenocarcinoma using a multisource cross-modal transformer modelhttps://www.pharmaradar360.com/article/0977ec49c350f4b2PharmaRadar360en2026-04-17T00:00:00.000ZAuthor Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trialhttps://www.pharmaradar360.com/article/06c3c44baa2f5959PharmaRadar360en2026-04-17T00:00:00.000ZPublisher Correction: Reliability of LLMs as medical assistants for the general public: a randomized preregistered studyhttps://www.pharmaradar360.com/article/4635853071fb1ef6PharmaRadar360en2026-04-17T00:00:00.000ZA roadmap to competitive preclinical packageshttps://www.pharmaradar360.com/article/1391c0c9f7f11276PharmaRadar360en2026-04-17T00:00:00.000ZImmune-stealth DNA for large cargo integrationhttps://www.pharmaradar360.com/article/cd67c72edf2b03eePharmaRadar360en2026-04-17T00:00:00.000ZSite-specific engineering to produce CAR T cells in vivohttps://www.pharmaradar360.com/article/62ce416b8fb44b31PharmaRadar360en2026-04-17T00:00:00.000ZWorld’s first two iPSC therapies in Japanhttps://www.pharmaradar360.com/article/3ddb66d55e0efd04PharmaRadar360en2026-04-17T00:00:00.000ZBiotech news from around the worldhttps://www.pharmaradar360.com/article/b092d25cf0cb3409PharmaRadar360en2026-04-17T00:00:00.000ZFDA approves wearable device for pancreatic cancerhttps://www.pharmaradar360.com/article/a8653d9aaa1c3a50PharmaRadar360en2026-04-17T00:00:00.000ZChina approves brain chip to overcome paralysishttps://www.pharmaradar360.com/article/3cdf06b4cb07867cPharmaRadar360en2026-04-17T00:00:00.000ZPlastic-eating fungi dig diapershttps://www.pharmaradar360.com/article/fb4186ac6bc1e7d0PharmaRadar360en2026-04-17T00:00:00.000ZNew gene-editing approaches for β-hemoglobinopathieshttps://www.pharmaradar360.com/article/ab8586e39794b18ePharmaRadar360en2026-04-17T00:00:00.000ZBriefing Chat: Penguins pick up PFAS pollutionhttps://www.pharmaradar360.com/article/720530035de622a7PharmaRadar360en2026-04-17T00:00:00.000ZUS lawmakers intensify scrutiny of scientific-publishing practiceshttps://www.pharmaradar360.com/article/0b756b27f164ed4cPharmaRadar360en2026-04-17T00:00:00.000ZImmune cells have a surprising role in exercise endurancehttps://www.pharmaradar360.com/article/1720f50175198c1ePharmaRadar360en2026-04-17T00:00:00.000ZNew year, old mehttps://www.pharmaradar360.com/article/ed3bd73f62a5c19bPharmaRadar360en2026-04-17T00:00:00.000ZRealizing the promise of CAR-T cell therapies for autoimmune diseaseshttps://www.pharmaradar360.com/article/99c5ec81deb27554PharmaRadar360en2026-04-17T00:00:00.000ZHypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Integrating Pharmacologic, Device, and Advanced Heart Failure Therapieshttps://www.pharmaradar360.com/article/a7ee61b5c0854038PharmaRadar360en2026-04-17T00:00:00.000ZÖppet seminarium om akademisk frihet: ”Vi måste fortsätta kämpa för Ahmadreza Djalali”https://www.pharmaradar360.com/article/f40da729a08fecc2PharmaRadar360en2026-04-17T00:00:00.000ZNeurotechEU-Decide: Joint Autumn School on Decision-Making (Gemensam höstskola om beslutsfattande)https://www.pharmaradar360.com/article/cab06d9c888a203bPharmaRadar360en2026-04-17T00:00:00.000ZKI-professor uppmärksammas för sitt arbete med sociala medierhttps://www.pharmaradar360.com/article/e5e38a7b33e53fd6PharmaRadar360en2026-04-17T00:00:00.000ZKarolinska Institutet får 6.2 miljoner till epilepsiforskning tillsammans med Danderyds sjukhushttps://www.pharmaradar360.com/article/97d95205fcacf83bPharmaRadar360en2026-04-17T00:00:00.000ZCharlotte Ytterberg får 2,7 miljoner kr från Familjen Kamprads stiftelsehttps://www.pharmaradar360.com/article/d44dd69802c1b5ffPharmaRadar360en2026-04-17T00:00:00.000ZAnslag för att undersöka nasal tillförsel av nervtillväxtfaktor vid Alzheimers sjukdomhttps://www.pharmaradar360.com/article/dc8ee6c0786c408aPharmaRadar360en2026-04-17T00:00:00.000ZCentral Valley unites around leading cause of death in womenhttps://www.pharmaradar360.com/article/860bac9ae5d7b59bPharmaRadar360en2026-04-17T00:00:00.000ZHow Our Diet Can Help Us Age Gracefullyhttps://www.pharmaradar360.com/article/ae78493b54e889cdPharmaRadar360en2026-04-16T22:44:32.000ZPosse na Escola de Belas Artes tem performance e marca início de nova gestãohttps://www.pharmaradar360.com/article/2fb3dbe4f0b77e58PharmaRadar360en2026-04-16T22:43:50.000ZModeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Sciencehttps://www.pharmaradar360.com/article/a6fbb01c250eeabcPharmaRadar360en2026-04-16T22:04:43.000ZARTIFICIAL INTELLIGENCE - The AI-Driven Path to Precision Therapeuticshttps://www.pharmaradar360.com/article/d279d03688eddfb8PharmaRadar360en2026-04-16T22:00:54.000ZAllogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stockhttps://www.pharmaradar360.com/article/c560142ee93fe9fePharmaRadar360en2026-04-16T22:00:00.000ZMichael Reth: “Las personas con dislexia están especializadas en explorar lo desconocido”https://www.pharmaradar360.com/article/e661a1478c15cda1PharmaRadar360en2026-04-16T21:08:38.000ZNew guidelines recommend AI-based breast cancer risk assessmentshttps://www.pharmaradar360.com/article/5cf159013578a687PharmaRadar360en2026-04-16T21:02:59.000ZENSEÑANZAhttps://www.pharmaradar360.com/article/8f24b91f0e7105d9PharmaRadar360en2026-04-16T21:01:17.000ZPregrado universitariohttps://www.pharmaradar360.com/article/ff2346ccbcb95487PharmaRadar360en2026-04-16T21:00:05.000ZSecretaría de Asuntos Académicoshttps://www.pharmaradar360.com/article/7d8d91b600a81b1ePharmaRadar360en2026-04-16T20:51:00.000ZDare to Dream: A Mission to Advance Pediatric Cancer Researchhttps://www.pharmaradar360.com/article/b39816f607a7c7edPharmaRadar360en2026-04-16T20:33:45.000ZFDA clears first AI-enabled, detector-based spectral CT systemhttps://www.pharmaradar360.com/article/a2f1306db8293649PharmaRadar360en2026-04-16T20:05:00.000ZEmergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibilityhttps://www.pharmaradar360.com/article/cf5c0228090fc064PharmaRadar360en2026-04-16T20:05:00.000ZEmergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026https://www.pharmaradar360.com/article/bc07fdca92bf23e5PharmaRadar360en2026-04-16T19:45:00.000ZStudy suggests link between prenatal exposure to certain medications and increased autism riskhttps://www.pharmaradar360.com/article/22892198cc80e2d9PharmaRadar360en2026-04-16T19:08:35.000ZAccelerating Safety Assessment to Proof-of-Concept ~Six Months Ahead of Industry Norms for a Novel Incretin-Based Therapeutichttps://www.pharmaradar360.com/article/114a5fe0bd9ca6a5PharmaRadar360en2026-04-16T19:06:20.000ZBIOAVAILABILITY & SOLUBILITY - Formulation Strategies for Tackling Poor Oral Bioavailabilityhttps://www.pharmaradar360.com/article/25422cc9b53e76daPharmaRadar360en2026-04-16T19:03:14.000ZRFK Jr. defends FDA, Makary following Republican questions